Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408156 | 1.00 | APAF1 (0.57) | APAF1CA12CA7CA9CA14 | |
| SCHEMBL2408159 | 1.00 | APAF1 (0.57) | APAF1CA12CA7CA9CA14 | |
| SCHEMBL1222340 | 0.90 | MAPT (0.49) | APAF1CA12CA7CA9CA14 | |
| SCHEMBL4676209 | 0.86 | APAF1 (0.54) | APAF1CA12CA7CA9CA14 | |
| SCHEMBL4676206 | 0.86 | APAF1 (0.54) | APAF1CA12CA7CA9CA14 | |
| SCHEMBL25297216 | 0.85 | APAF1 (0.53) | APAF1KMT2AMEN1CYP3A4CHRM2 | |
| SCHEMBL25831273 | 0.85 | APAF1 (0.53) | APAF1KMT2AMEN1CYP3A4CHRM2 | |
| SCHEMBL4680133 | 0.85 | ALDH1A1 (0.53) | APAF1KMT2AMEN1CYP3A4CHRM2 | |
| SCHEMBL13720968 | 0.84 | ESR1 (0.45) | APAF1CA12CA7CA9CA14 | |
| SCHEMBL22004286 | 0.84 | MEN1 (0.43) | APAF1KMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676263-B1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. | 2021-07-06 | — | — | US | disclosed |
| US-10786491-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3676263-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2020-07-08 | — | — | EP | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2020-06-11 | — | — | US | disclosed |
| EP-3426638-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019043103-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-03-07 | — | — | WO | disclosed |
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-02-21 | — | — | US | disclosed |
| EP-3426638-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2019-01-16 | — | — | EP | disclosed |
| CN-109071457-A | Inhibitors of indoleamine 2, 3-dioxygenase | 荷兰转化研究中心有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| WO-2017153459-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-09-14 | — | — | WO | disclosed |
| US-9750729-B2 | Immunomodulation by IAP inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| EP-1076663-B1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6369034-B1 | FOR THERAPY OF CANCER, RESTENOSIS, AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH2 | APAF1 2387/4885CA12 1631/4885CA7 2213/4885 |
| US-10786491-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | APAF1 12/4885CA12 2150/4885CA7 2123/4885 |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | APAF1 3028/4885CA12 2661/4885CA7 2751/4885 |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | APAF1 4195/4885CA12 4866/4885CA7 4874/4885 |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | APAF1 3028/4885CA12 2661/4885CA7 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.